Posted by Michael Wonder on 05 Oct 2018
Gilead strikes deal with NHS England on CAR-T Yescarta
5 October 2018 - NHS England claims adult leukaemia access is first in Europe.
NHS England has agreed a market access deal with Gilead for its groundbreaking CAR-T therapy Yescarta, and is claiming it to be the first European deal.
The agreement follows swiftly behind a similar deal between NHS England and Novartis for its rival CAR-T treatment Kymriah in children with acute lymphoblastic leukaemia, where around 30 children in the country are year stand to benefit.
Today’s agreement will see around 200 adult patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma be eligible for treatment.
